Jul. 26 at 1:26 PM
$RNXT
RenovoGem™, RenovoRx’s lead product candidate, is positioned to address the high unmet need in treating locally advanced pancreatic cancer (LAPC). The current standard of care for LAPC includes chemotherapy regimen, which offer a median overall survival of 12 - 18.8 months from diagnosis.
However, only 3 drugs have been approved by the FDA for LAPC in the past decade, each providing less than a 2-month median overall survival benefit and associated with increased toxicity rates. RenovoGem aims to surpass these benchmarks, with independent interviews suggesting oncologists would likely adopt RenovoGem if it demonstrates a 4-month overall survival benefit and improved toxicity profile
Additionally, RenovoRx’s strong intellectual property and regulatory designations, such as FDA Orphan Drug status, provide valuable market exclusivity and protection. These factors enhance RenovoRx’s attractiveness as an investment, indicating substantial growth and potential returns for investors
